Endogenous interferon-beta but not interferon-alpha or interferon-lambda levels in nasal mucosa predict clinical outcome in critical COVID-19 patients independent of viral load

Soraya Maria Menezes, Marcos Braz, Veronica Llorens-Rico Joost Wauters, Johan Van Weyenberg

Affiliations:

SMM, MB, JVW: Laboratory of Clinical and Epidemiological Virology, Dept. of Microbiology, Immunology and Transplantation, Rega Institute of Medical Research, KU Leuven, Leuven, Belgium.

VLR: Laboratory of Bacteriology, Dept. of Microbiology, Immunology and Transplantation, Rega Institute of Medical Research, KU Leuven, Leuven, Belgium.

JW: Laboratory for Clinical Infectious and Inflammatory Disorders, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Abstract:

Although the subject of intensive preclinical and clinical research, controversy on the protective vs. deleterious effect of interferon (IFN) in COVID-19 remains. Some apparently conflicting results are likely due to the intricacy of IFN subtypes (type I: IFN-alpha/beta, type III: IFN-lambda), timing and mode of administration (nebulized/subcutaneous) and clinical groups targeted (asymptomatic/mild, moderate, severe/critical COVID-19). Within the COntAGlouS (COvid-19 Advanced Genetic and Immunologic Sampling) clinical trial, we investigated endogenous type I and type III IFNs in nasal mucosa as possible predictors of clinical outcome in critical patients, as well as their correlation to SARS-CoV-2 viral load, using nCounter technology. We found that endogenous IFN-beta expression in the nasal mucosa predicts clinical outcome, independent of viral replication or Apache II score, and should be considered as a prognostic tool in a precision medicine approach of IFN therapy in COVID-19 clinical management.

INTRODUCTION

Although the subject of intensive preclinical and clinical research, controversy on the protective vs. deleterious effect of interferon (IFN) in COVID-19 remains. Some apparently conflicting results are likely due to the intricacy of IFN subtypes (type I: IFN- α /beta, type III: IFN- λ), timing and mode of administration (nebulized/subcutaneous) and clinical groups targeted (asymptomatic/mild, moderate, severe/critical COVID-19).

Two recent phase-2 clinical trials^{1,2} reporting the use of type I and type III IFN achieved their primary clinical and virological outcomes in hospitalized and ambulatory COVID-19 patients, respectively. As set forth previously³, understanding the different kinetics of endogenous IFN production in mild and severe COVID-19 patients, relative to viral replication, will help identify the therapeutic window. Thus, endogenous IFN(s) add another layer of complexity to the COVID-19 IFN conundrum but have been understudied in critical (ICU) patients.

PATIENTS AND METHODS

The COntAGlous trial (COvid-19 Advanced Genetic and Immunologic Sampling; an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2) proposes a transdisciplinary approach to identify host factors resulting in hyper-susceptibility to SARS-CoV-2 infection. Within this prospective clinical trial (NCT04327570), we investigated viral and host transcriptomes in the nasal mucosa of patients with COVID-19 critical disease, admitted to the intensive care unit (ICU) at University Hospitals Leuven, Belgium. Nasal swabs were collected from 57 critical COVID-19 patients on admission in ICU and/or first bronchoscopy. RNA was extracted and mRNA levels for IFN- β (*IFNB1* gene), IFN- α (*IFNA2* gene) and IFN- λ (*IFNL2* and *IFNL3* genes) were quantified by nCounter technology (Nanostring) as previously described⁴. Viral load (total SARS-CoV-2 transcripts corresponding to Surface glycoprotein, Nucleoprotein, Envelope protein, Membrane protein, ORF1AB, ORF3A and ORF7A) was quantified as described⁵, using digital transcriptomics (nCounter, Nanostring) previously validated in a large cohort of acute respiratory infection⁶. All ICU patients received standard-of-care treatment (corticosteroids, anticoagulants, vasopressors and/or antibiotics, in addition to ventilation/ECMO) but none received IFN treatment.

RESULTS AND DISCUSSION

As primary endpoint, we investigated length of stay in the ICU (ranging from 3 to 74 days) with type I and III IFN as predictors, using Kaplan-Meier curves. As shown in Fig. 1A-B-C, *IFNB1* transcript levels (Hazard ratio (HR) 0.30 95%CI[0.16-0.56], $p=0.0001$) but not *IFNA2* (HR 0.82 95%CI[0.46-1.50], $p=0.53$) or *IFNL2/IFNL3* transcript levels (HR 0.67 95%CI[0.35-1.27], $p=0.22$), nor viral load (HR 1.13 95%CI[0.64-1.98], $p=0.68$, data not shown) predicted the length of ICU stay. Multivariable regression confirmed *IFNB1* levels ($\beta=0.45$ [0.24-0.67], $p=0.0002$) and Acute Physiology and Chronic Health Evaluation (Apache) II score ($\beta=1.06$ [0.49-1.65], $p=0.0009$) as independent predictors, whereas viral load, age, gender, BMI or Charlson Comorbidity index were not. Moreover, *IFNB1* levels also predicted worse

clinical outcome measured by maximal WHO ordinal scale or maximal oxygen support (Mann-Whitney, $p=0.027$ and $p=0.0068$, respectively), as well as a composite score (discharge to rehabilitation centre, hospital stay >60 days or death; Mann-Whitney $p=0.040$). Noteworthy, 45% (5 of 11) of *IFNB1*-positive patients required ECMO vs. only 9% (4 of 46) of *IFNB1*-negative patients. The total days on ECMO was also higher in *IFNB1*+ patients (median 24.0 vs. 10.5 days, Mann-Whitney $p=0.016$). *IFNB1* levels also predicted multi-organ involvement, another hallmark of critical COVID-19, as measured by Sequential Organ Failure Assessment (SOFA) score (median SOFA score 7 for *IFNB1*-negative vs. 12 for *IFNB1*+, Mann-Whitney $p=0.0072$). Surprisingly, *IFNB1* levels were not correlated to viral load (Fig. 1D), in contrast to *IFNA2* ($r=0.45$, $p=0.0007$) and *IFNL2/IFNL3* ($r=0.47$, $p=0.0003$).

In conclusion, endogenous IFN-beta production in the nasal mucosa predicts clinical outcome, independent of viral replication or Apache II score, and should be considered as a prognostic tool in a precision medicine approach of IFN therapy in COVID-19 clinical management.

Fig. 1: Upper respiratory tract IFN-beta transcript levels, but not IFN-alpha or IFN-lambda transcript levels, predict length of ICU stay in critical COVID-19 patients. Kaplan-Meier curves of (A) *IFNB1*-positive vs. *IFNB1*-negative, (B) *IFNA2*-positive vs. *IFNA2*-negative, and (C) *IFNL2/3*-positive vs. *IFNL2/3*-negative ICU patients were compared using Log-rank test (** $p=0.0001$ for *IFNB1*, not significant for *IFNA2*, *IFNL2/IFNL3* or viral load, not shown). (D) Viral load was correlated to *IFNB1*, *IFNA2*, and *IFNL2/IFNL3* transcripts (Spearman correlation). Viral load and *IFNL2/IFNL3* data were missing from 3 patients ($n=54$).

References:

1. Feld et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *Lancet Respir Med* 2021 [https://doi.org/10.1016/S2213-2600\(20\)30566-X](https://doi.org/10.1016/S2213-2600(20)30566-X)
2. Monk et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med* 2021 [https://doi.org/10.1016/S2213-2600\(20\)30511-7](https://doi.org/10.1016/S2213-2600(20)30511-7)
3. Park & Iwasaki. Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host & Microbe* 2020. <https://doi-org/10.1016/j.chom.2020.05.008>
4. Fukutani et al. In situ Immune Signatures and Microbial Load at the Nasopharyngeal Interface in Children with Acute Respiratory Infection. *Front Microbiol.* 2018 Nov 9;9:2475. <https://doi-org/10.3389/fmicb.2018.02475>
5. Ackermann et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med.* 2020 Jul 9;383(2):120-128. <https://doi-org/10.1056/NEJMoa2015432>
6. Bouzas et al. Diagnostic accuracy of digital RNA quantification versus real-time PCR for the detection of respiratory syncytial virus in nasopharyngeal aspirates from children with acute respiratory infection. *J Clin Virol.* 2018 Sep;106:34-40. <https://doi-org/10.1016/j.jcv.2018.07.003>